A trend over time study of hepatic Farnesoid-X-activated receptor and its downstream targets modulation by valproic acid in mice

References

• Abdelkader NF, Elyamany M, Gad AM, Assaf N, Fawzy HM, Elesawy WH. 2020. Ellagic acid attenuates liver toxicity induced by valproic acid in rats. J Pharmacol Sci. 143(1):23–29. doi: 10.1016/j.jphs.2020.01.007.
   PubMed Web of Science ®Google Scholar
• Aljarboa AS, Alhusaini AM, Sarawi WS, Mohammed R, Ali RA, Hasan IH. 2023. The implication of LPS/TLR4 and FXR receptors in hepatoprotective efficacy of indole-3-acetic acid and chenodeoxycholic acid. Life Sci. 334:122182. doi: 10.1016/j.lfs.2023.122182.
   PubMed Web of Science ®Google Scholar
• Armstrong LE, Grace, LG. 2017. Role of FXR in liver inflammation during nonalcoholic steatohepatitis. Curr Pharmacol Rep. 3(2):92–100. doi: 10.1007/s40495-017-0085-2.
   PubMedGoogle Scholar
• Caiment F, Wolters J, Smit E, Schrooders Y, Kleinjans J, van den Beucken T. 2020. Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBPα-controlled gene expression. Arch Toxicol. 94(10):3463–3473. doi: 10.1007/s00204-020-02835-x.
   PubMed Web of Science ®Google Scholar
• Chang TKH, Abbott FS. 2006. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev. 38(4):627–639. doi: 10.1080/03602530600959433.
   PubMed Web of Science ®Google Scholar
• Claudel T, Staels B, Kuipers F. 2005. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arteriosclerosis Thrombosis Vasc Biol. 25(10):2020–2031.
   PubMed Web of Science ®Google Scholar
• Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC, Wahlström A, Ashby JW, et al. 2021. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 33(8):1671–1684.e4. doi: 10.1016/j.cmet.2021.06.012.
   PubMed Web of Science ®Google Scholar
• Dong L, Han X, Tao X, Xu L, Xu Y, Fang L, Yin L, Qi Y, Li H, Peng J, et al. 2018. Protection by the total flavonoids from Rosa Laevigata Michx fruit against lipopolysaccharide-induced liver injury in mice via modulation of FXR signaling. Foods. 2018; 7(6):88. doi: 10.3390/foods7060088.
   PubMed Web of Science ®Google Scholar
• Gai Z, Chu L, Xu Z, Song X, Sun D, Kullak-Ublick GA. 2017. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci Rep. 7(1):9815.
   Google Scholar
• Gai Z, Krajnc E, Samodelov SL, Visentin M, Kullak-Ublick GA. 2020. Obeticholic acid ameliorates valproic acid–induced hepatic steatosis and oxidative stress. Mol Pharmacol. 97(5):314–323. doi: 10.1124/mol.119.118646.
   PubMed Web of Science ®Google Scholar
• Heidari R, Jafari F, Khodaei F, Shirazi Yeganeh B, Niknahad H. 2018. Mechanism of valproic acid-induced Fanconi syndrome involves mitochondrial dysfunction and oxidative stress in rat kidney. Nephrology. 23(4):351–361. doi: 10.1111/nep.13012.
   PubMed Web of Science ®Google Scholar
• Jamshidi V, Hashemi SA, Khalili A, Fallah P, Ahmadian-Attari MM, Beikzadeh L, Mazloom R, Najafizadeh P, Bayat G. 2021. Saffron offers hepatoprotection via up-regulation of hepatic farnesoid-x-activated receptors in a rat model of acetaminophen-induced hepatotoxicity. Avicenna J Phytomed. 11(6):622–632.
   PubMed Web of Science ®Google Scholar
• Jin D, Lu T, Ni M, Wang H, Zhang J, Zhong C, Shen C, Hao J, Busuttil RW, Kupiec-Weglinski JW, et al. 2020. Farnesoid X Receptor Activation Protects Liver From Ischemia/Reperfusion Injury by Up-Regulating Small Heterodimer Partner in Kupffer Cells. Hepatol Commun. 4(4):540–554. doi: 10.1002/hep4.1478.
   PubMed Web of Science ®Google Scholar
• Jin J, Xiong T, Hou X, Sun X, Liao J, Huang Z, Huang M, Zhao Z. 2014. Role of Nrf2 activation and NF-κB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice. Food Chem Toxicol. 73:95–104. doi: 10.1016/j.fct.2014.08.009.
   PubMed Web of Science ®Google Scholar
• Kaspar JW, Niture SK, Jaiswal AK. 2009. Nrf2: INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 47(9):1304–1309. doi: 10.1016/j.freeradbiomed.2009.07.035.
   PubMed Web of Science ®Google Scholar
• Khalili A, Fallah P, Hashemi SA, Ahmadian-Attari MM, Jamshidi V, Mazloom R, Beikzadeh L, Bayat G. 2021. New mechanistic insights into hepatoprotective activity of milk thistle and chicory quantified extract: the role of hepatic Farnesoid-X activated receptors. Avicenna J Phytomed. 11(4):367–379. doi: 10.22038/AJP.2020.17281.
   PubMed Web of Science ®Google Scholar
• Li C, Yang J, Wang Y, Qi Y, Yang W, Li Y. 2020. Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. Front Pharmacol. 11:1247. doi: 10.3389/fphar.2020.01247.
   PubMed Web of Science ®Google Scholar
• Manley S, Ni H-M, Williams JA, Kong B, DiTacchio L, Guo G, Ding W-X. 2014. Farnesoid X receptor regulates forkhead box O3a activation in ethanol-induced autophagy and hepatotoxicity. Redox Biol. 2:991–1002. doi: 10.1016/j.redox.2014.08.007.
   PubMed Web of Science ®Google Scholar
• Punapart M, Eltermaa M, Oflijan J, Sütt S, Must A, Kõks S, Schalkwyk LC, Fernandes C, Vasar E, Soomets U, et al. 2014. Effect of chronic valproic acid treatment on hepatic gene expression profile in Wfs1 knockout mouse. PPAR Res. 2014:349525–349511. doi: 10.1155/2014/349525.
   PubMed Web of Science ®Google Scholar
• Safari F, Hajiadeh S, Moshtaghion SH, Forouzandeh Moghadam M, Shekarforoush S, Bayat G, Mazlum R, Sattarian L. 2012. Effect of Losartan on NOX2 transcription following acute myocardial ischemia-reperfusion. Physiol Pharmacol. 16(1):44–53.
   Google Scholar
• Shin SM, Yang JH, Ki SH. 2013. Role of the Nrf2-are pathway in liver diseases. Oxid Med Cell Longev. 2013:763257–763259. doi: 10.1155/2013/763257.
   PubMed Web of Science ®Google Scholar
• Tang W, Abbott FS. 1996. Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates. Chem Res Toxicol. 9(2):517–526. doi: 10.1021/tx950120y.
   PubMed Web of Science ®Google Scholar
• Tung EWY, Winn LM. 2011. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Mol Pharmacol. 80(6):979–987. doi: 10.1124/mol.111.072314.
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. 2008. Farnesoid X receptor antagonizes nuclear factor ΚB in hepatic inflammatory response. Hepatology. 48(5):1632–1643. doi: 10.1002/hep.22519.
   PubMed Web of Science ®Google Scholar
• Xiong L, Xie J, Song C, Liu J, Zheng J, Liu C, Zhang X, Li P, Wang F. 2015. The activation of Nrf2 and its downstream regulated genes mediates the antioxidative activities of Xueshuan Xinmaining tablet in human umbilical vein endothelial cells. Evidence-Based Complement Alternat Med. 2015:1–7. doi: 10.1155/2015/187265.
   Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, Harnish DC. 2009. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 51(2):380–388. doi: 10.1016/j.jhep.2009.03.025.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu Y, Qi Y, Xu L, Song S, Yin L, Tao X, Zhen Y, Han X, Ma X, et al. 2017. Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. Toxicology. 378:53–64. doi: 10.1016/j.tox.2017.01.007.
   PubMed Web of Science ®Google Scholar